Mineralys Therapeutics (NasdaqGS:MLYS) Q4 2025 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsAdam Levy - CFODan Ferry - Managing DirectorDavid Rodman - Chief Medical OfficerEric Warren - Chief Commercial OfficerJon Congleton - CEOConference Call ParticipantsAnnabel Samimy - Managing Director and Senior Research AnalystGeorgia Bank - Equity Research AnalystJason Gerberry - Senior AnalystMichael DiFiore - Director and Equity Research AnalystMohit Bansal - Managing Director and Senior AnalystRam ...

Financial Data and Key Metrics Changes - In Q4 2025, net sales decreased by 20.6% to $87.7 million compared to $110.5 million in Q4 2024 [15] - Full-year net sales were down 6.7%, totaling $368.3 million in 2025 versus $394.9 million in 2024 [15] - Adjusted non-GAAP profit for Q4 2025 was $26.1 million, or 29.7% of sales, up from 28.4% in Q4 2024 [16] - Full-year adjusted non-GAAP net income was $4.2 million, or $0.31 per share, compared to a loss of $0.6 million, or $0.05 per share in 2024 [20] Business Line Data and Key Metrics Changes - Connected Home channel sales increased by $17.1 million, or 15.8%, to $125.4 million for the full year [15] - In Q4 2025, Connected Home sales were down 13.7% to $29.7 million, driven by lower HASH and HVAC sales [16] - Home entertainment sales decreased by $43.7 million, or 15.2%, to $242.9 million for the full year [16] Market Data and Key Metrics Changes - The company noted a structural decline in parts of the home entertainment business and a softening in the connected home market [9] - Customer forecasts and orders indicated that revenue inflection in Connected Home would take longer than expected [10] Company Strategy and Development Direction - The company is focused on restructuring to align with the revenue and margin profile for 2026, including a reduction in force and cost reductions across various areas [11] - The strategy includes optimizing R&D and portfolio focus on high-revenue and high-margin opportunities [11] - The company aims to improve operational efficiency, strengthen profitability, and generate more free cash flow [23] Management Comments on Operating Environment and Future Outlook - Management acknowledged continued turbulence in home entertainment and a tempered outlook for Connected Home products [8] - The company is not providing quarterly guidance for fiscal year 2026, focusing instead on delivering a full-year plan [12] - Management emphasized the need for structural changes to improve margins and cash generation [19] Other Important Information - The company achieved a positive net cash position for the first time since 2021, with a net cash balance of $8.2 million [20] - The company executed a reduction in force (RIF) of approximately 50 people in Q4 [27] Q&A Session Summary Question: What is the expected decline in revenue for 2026? - Management stated that due to revenue uncertainty, they cannot provide specifics on the expected decline [25] Question: How much more expense reduction is planned from the Q4 run rate? - Management indicated that the operating expenses would be significantly reduced, aligning costs with revenue [26] Question: What percentage of headcount was affected by the RIF in Q4? - The RIF in Q4 affected around 50 people [27] Question: What significant customers did the company have in Q4? - Major customers included Daikin at close to 16% and Comcast at close to 11% [31] Question: Was the licensing revenue in Q4 from traditional home entertainment or connected home? - The licensing revenue was primarily from the traditional business, with plans to expand in connected home [32]

Funko (NasdaqGS:FNKO) Q4 2025 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsJosh Simon - CEOKatie Wilson - Influencer Marketing ManagerYves Le Pendeven - CFONone - Video NarratorKatie WilsonHi everyone, and welcome to Funko's 2025 fourth quarter financial results conference call. I'm Katie Wilson, and I'm here at the Funko store in Hollywood. With me are Josh Simon, our Chief Executive Officer, and Yves Le Pendeven, our Chief Financial Officer. Welcome guys.Josh SimonHello.Katie WilsonJosh, I ...

Vaxart (NasdaqCM:VXRT) Q4 2025 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsCheng Li - Director of Biotech Equity ResearchEdward Berg - SVP and General CounselJames Cummings - CMOJeroen Grasman - CFOMayank Mamtani - Senior Managing Director and Group Head of Healthcare ResearchSean Tucker - Founder and Chief Scientific OfficerSteven Lo - President and CEOOperatorGreetings, and welcome to the Vaxart fourth quarter business update and year-end 2025 financial results conference call. A question ...

SentinelOne (NYSE:S) Q4 2026 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsAdam Tindle - Managing DirectorBarry Padgett - Interim CFOBrian Essex - Executive DirectorIttai Kidron - Managing DirectorJohn DiFucci - Senior Managing DirectorJoseph Gallo - SVPMeta Marshall - Managing DirectorRichard Poland - VP of Equity ResearchRoger Boyd - Executive DirectorSaad Nazir - Head of Investor RelationsShaul Eyal - Managing Director of Equity ResearchTomer Weingarten - CEOConference Call ParticipantsEri ...

Vuzix (NasdaqCM:VUZI) Q4 2025 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsEd McGregor - Director of Investor RelationsGrant Russell - CFO and EVPPaul Travers - President and CEOConference Call ParticipantsChristian Schwab - Senior Research AnalystOperatorLadies and gentlemen, thank you for standing by. Our conference will be getting started momentarily. Please continue to hold. Once again, our conference will be getting started momentarily. Please continue to hold. Please stand by. Greeting ...

Capricor Therapeutics (NasdaqCM:CAPR) Q4 2025 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsAJ Bergmann - CFOLinda Marbán - CEOConference Call ParticipantsBoobalan Pachaiyappan - Managing Director and Senior Biotech AnalystCatherine Novack - Healthcare AnalystEdward Tenthoff - Managing Director and Senior Research AnalystJoe Pantginis - Managing Director and Senior Healthcare AnalystKristen Kluska - Managing Director and Biotechnology Equity Research AnalystLeland Gershell - Managing Director ...

Corvus Pharmaceuticals (NasdaqGM:CRVS) Q4 2025 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsLeiv Lea - CFOLi Watsek - DirectorRichard Miller - CEOSean Lee - VP of Equity ResearchZack Kubow - Senior Group Director of Investor RelationsConference Call ParticipantsAydin Huseynov - Equity Research AnalystGraig Suvannavejh - Senior AnalystJeff Jones - Managing Director and Senior AnalystRoger Song - Senior Equity Research AnalystOperatorGood afternoon, everyone, and thank you for standing by and ...

The Beauty Health Company (NasdaqCM:SKIN) Q4 2025 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsAlec Legg - VP of Equity ResearchJP Wollam - Equity Research AssociateMike Monahan - CFONorberto Aja - Managing DirectorPedro Malha - CEOConference Call ParticipantsAllen Gong - VP and Equity Research AnalystBruce Jackson - Senior AnalystJoe Federico - VP and Equity Research AnalystJonna Kim - VP and Senior Equity Research AnalystOperatorday, and welcome to The Beauty Health Company 2025 fourth qua ...

Zedge (NYSEAM:ZDGE) Q2 2026 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsBrian Siegel - Senior Managing DirectorJonathan Reich - CEOYi Tsai - CFOConference Call ParticipantsAllen Klee - Managing Director and Senior Equity Research AnalystOperatorGood day, ladies and gentlemen, and welcome to Zedge's Earnings Conference Call for the second fiscal quarter of 2026. During management's prepared remarks, all participants will be in a listen-only mode. Should you need assistance, please signal a c ...